TAB1(N-term) Antibody (YA5232)

Cat. No.: HY-P85540: Data Sheet User Guide for Antibodies
FAQs
Technical Support

TAB1(N-term) Antibody (YA5232) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to TAB1(N-term).

For research use only. We do not sell to patients.

Size		Stock
50 μL		Get quote
100 μL		Get quote

* Please select Quantity before adding items.

WB: Western Blot;
IHC-P: Immunohistochemistry-Paraffin;
IHC-F: Immunohistochemistry-Frozen;
ICC/IF: Immunocytochemistry/Immunofluorescence;
IF-Tissue: Immunofluorescence-Tissue;
mIHC: Multiplex Immunohistochemical;
IP: Immunoprecipitation;
ChIP: Chromatin Immunoprecipitation;
FC: Flow Cytometry;
ELISA: Enzyme Linked Immunosorbent Assay

Product Detail
Background
Documentation

Description

TAB1(N-term) Antibody (YA5232) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to TAB1(N-term).

Host

Mouse

Clonality

Monoclonal

Molecular Weight

Observed band size: 55 kDa

Note: Due to possible protein modifications or aggregation, the molecular weight should be confirmed by actual measurement, and the predicted value is for reference only.

Species Reactivity

Human

SwissProt ID

Q15750

Gene ID

10454 [NCBI]

Immunogen

Purified recombinant human TAB1(N-terminus) protein fragments expressed in E.coli.

Application &
Dilution Ratio

Application	Dilution Ratio
WB WB: Western Blot	1:1000

Purity	affinity chromatography.	Conjugation	Non-conjugated
Modification	Unmodified

Appearance

Liquid

Formulation

Supplied in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

Storage & Stability

Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.

Shipping

Shipping with blue ice.

Background

Function：Key adapter protein that plays an essential role in JNK and NF-kappa-B activation and proinflammatory cytokines production in response to stimulation with TLRs and cytokines (PubMed:22307082, PubMed:24403530). Mechanistically, associates with the catalytic domain of MAP3K7/TAK1 to trigger MAP3K7/TAK1 autophosphorylation leading to its full activation (PubMed:10838074, PubMed:25260751, PubMed:37832545). Similarly, associates with MAPK14 and triggers its autophosphorylation and subsequent activation (PubMed:11847341, PubMed:29229647). In turn, MAPK14 phosphorylates TAB1 and inhibits MAP3K7/TAK1 activation in a feedback control mechanism (PubMed:14592977). Also plays a role in recruiting MAPK14 to the TAK1 complex for the phosphorylation of the TAB2 and TAB3 regulatory subunits (PubMed:18021073)

Subcellular Localization：Cytoplasm, cytosol; Endoplasmic reticulum membrane; Peripheral membrane protein; Cytoplasmic side

Expression：
Tissue_specificity:general expression

Isoforms & Post-Translational Modification：Q15750 has 2 isomers: Q15750-1: 54644 Da (predicted); Q15750-2: 49917 Da (predicted).
Phosphorylated at all three sites Ser-423, Thr-431 and Ser-438 by MAPK14 when cells were exposed to cellular stresses, or stimulated with TNF-alpha, IL1 or LPS (PubMed:14592977). These phosphorylations inhibit TAK1 activation by a feedback control mechanism (PubMed:14592977). Dephosphorylated by DUSP14 at Ser-438, leading to TAB1-MAP3K7/TAK1 complex inactivation in T-cells (PubMed:24403530);Ubiquitinated by MAP3K1 with 'Lys-63'-linked polyubiquitin; leading to activation of TAK1 and of JNK and p38 MAP kinases following EGF and TGF-beta stimulation (PubMed:25260751). Ubiquitinated by ITCH with 'Lys-48'-linked polyubiquitin; leading to proteasomal degradation (PubMed:25714464). Ubiquitinated by RNF114 during maternal-to-zygotic transition; leading to degradation (By similarity);(Microbial infection) Deubiquitinated by Y.enterocolitica YopP;O-GlcNAcylated at Ser-395 by OGT is required for full MAP3K7/TAK1 activation upon stimulation with IL-1 or osmotic stress (PubMed:22307082). Deglycosylated at Ser-395 by OGA (PubMed:28939839)

Subunit：Interacts with XIAP and BIRC7 (PubMed:11865055, PubMed:17560374). Interacts with TRAF6 and MAP3K7; during IL-1 signaling (PubMed:10094049, PubMed:10838074, PubMed:11323434, PubMed:8638164). Identified in the TRIKA2 complex composed of MAP3K7, TAB1 and TAB2 (PubMed:11460167). Interacts with TRAF6 and MAPK14; these interactions allow MAPK14 autophosphorylation (PubMed:11847341). Interacts with STING1; interaction takes place following cGAMP activation and promotes TAB1 recruitment to the endoplasmic reticulum, triggering MAP3K7/TAK1 activation and STING1 phosphorylation (PubMed:37832545)

Synonyms

2310012M03Rik; 3'-Tab1; MAP3K7IP 1; MAP3K7IP1; MGC57664; Mitogen activated protein kinase kinase kinase 7 interacting protein 1; Mitogen-activated protein kinase kinase kinase 7-interacting protein 1; TAB 1; TAB1; TAB1_HUMAN; TAK1 binding protein 1; TAK1-binding protein 1; TGF beta activated kinase 1 binding protein 1; TGF-beta activated kinase 1/MAP3K7 binding protein 1; TGF-beta-activated kinase 1 and MAP3K7-binding protein 1; TGF-beta-activated kinase 1-binding protein 1; Transforming growth factor beta activated kinase binding protein 1.

Documentation

User Guide for Antibodies (1077 KB)